CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 136 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 12.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $107,000 | -18.9% | 13,810 | -31.7% | 0.01% | -28.6% |
| Q4 2020 | $132,000 | -74.5% | 20,213 | -74.0% | 0.01% | -57.6% |
| Q3 2020 | $517,000 | -51.6% | 77,763 | -39.4% | 0.03% | -55.4% |
| Q2 2020 | $1,069,000 | +658.2% | 128,274 | +596.7% | 0.07% | +640.0% |
| Q1 2020 | $141,000 | +48.4% | 18,411 | +43.2% | 0.01% | +25.0% |
| Q3 2019 | $95,000 | -27.5% | 12,855 | +10.4% | 0.01% | -33.3% |
| Q2 2019 | $131,000 | -62.6% | 11,642 | -64.2% | 0.01% | -52.0% |
| Q1 2019 | $350,000 | -22.2% | 32,530 | +65.4% | 0.02% | -19.4% |
| Q2 2018 | $450,000 | -35.0% | 19,670 | -19.1% | 0.03% | -35.4% |
| Q1 2018 | $692,000 | +46.0% | 24,318 | -6.9% | 0.05% | -59.7% |
| Q3 2017 | $474,000 | -55.0% | 26,110 | -57.2% | 0.12% | -11.9% |
| Q1 2017 | $1,053,000 | +466.1% | 60,979 | +260.8% | 0.14% | +365.5% |
| Q4 2016 | $186,000 | – | 16,900 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |